ArticleMultiple sclerosis and related disorders2025
Relapse and disability outcomes in incident MOGAD patients undergoing watchful waiting after onset.
Article in Multiple sclerosis and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study.Annals of clinical and translational neurology · 2026Article
- MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.Annals of clinical and translational neurology · 2026Article
- Article
- The relationship between serum MOG-IgG titer status and titers and the prognosis of pediatric MOGAD: a retrospective cohort study.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
backgroundObservation off chronic steroids-sparing immunotherapy (watchful waiting) is often recommended after the onset attack of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) given the variable relapse risk, but the outcomes of this approach are unexplored.
objectivesTo determine the risk of relapse and unfavorable disability outcomes in MOGAD patients who underwent watchful waiting approach after the onset attack.
methodsIn this international, multicenter, retrospective case series in four tertiary-care centers in Canada, Israel, Thailand, and the United States, patients who fulfilled the 2023 MOGAD diagnostic criteria, presented to the participating institutions with the first clinical attack (incident cases), and had at least 3 years of follow-up were identified (n = 81). Only incident cases were included to avoid referral bias.
resultsThe median age was 31 (IQR 18-47) years, 57 % were female, and the median follow-up was 6.3 (IQR 4.5-10.1) years. After onset, 65 (80 %) underwent watchful waiting. Forty-one (63 %) had relapses with annualized relapse rate of 0.27 (IQR 0.15-0.44). Unfavorable disability outcomes (Expanded Disability Status Scale score ≥2.0) were observed in 12/64 (19 %) watchful-waiting patients (7 from the onset attack; 4 from relapses; 1 unclear).
conclusionsGiven that one-third of watchful waiting patients remained monophasic and unfavorable disability outcomes from relapses were uncommon, a continued observation off chronic steroids-sparing immunotherapy could be an option for a subset of MOGAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.